Business
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
EL MONTE, Calif., April 22, 2026--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its abstract was selected to be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) rapid oral abstract session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in hall D1 of McCormick Place, Chicago.
About this update from Fulgent Genetics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/33eed3d7989cef7b293cbc19700a34c4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6mPyYZ57xro0mI4cmsP.2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/33eed3d7989cef7b293cbc19700a34c4","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.8lcOcMIbE39uefSrV6iQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/33eed3d7989cef7b293cbc19700a34c4","width":1024,"height":512}},"lazy":false},{"type":"text","content":"EL MONTE, Calif., April 22, 2026--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its abstract was selected to be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) rapid oral abstract session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in hall D1 of McCormick Place, Chicago.","length":524,"tagName":"p"},{"type":"text","content":"The abstract is entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)", clinical trial identifier, NCT06332092. This is a Phase 2 study designed to evaluate the efficacy of different dosing regimens as well as to characterize the pharmacokinetics (PK) and safety and tolerability of FID-007 in combination with cetuximab in patients with disease progression after treatment with PD-L1-based immune checkpoint inhibitor.","length":502,"tagName":"p"},{"type":"text","content":"Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer, said, "We are honored to be selected by ASCO to present our findings on the interim data of our Phase 2 results for FID-007. We are encouraged by the clinical progress achieved so far and believe in the potential of FID-007 for the treatment of (R/M) HNSCC patients, currently having very few effective treatment options."","length":408,"tagName":"p"},{"type":"text","content":"Details of the presentation are as follows:"...